A Dose Block-randomized, Double-blind, Placebo Controlled, Single and Multiple-dosing, Dose-escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, PK/PD of J2H-1702 After Oral Administration in Healthy Male Subjects
Latest Information Update: 26 Feb 2025
At a glance
- Drugs J2H-1702 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors J2H Biotech
Most Recent Events
- 18 Mar 2024 New trial record